A Revolutionary Approach to Cancer Treatment
Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefit to patients. Jounce utilizes its Translational Science Platform to first focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.
Year Invested: 2013
Location: Cambridge, Mass.